AstraZeneca (NYSE:AZN) announced today the launch of “click-to-chat” on CRESTOR.com and PurplePill.com. The new “click-to-chat” technology gives consumers an option to contact a live AstraZeneca customer service representative with just a click of a button. Click-to-chat is a live, online chat option, similar to instant messaging, and can be accessed at the “Contact Us” page of the CRESTOR® (rosuvastatin calcium) and NEXIUM® (esomeprazole magnesium) websites.
“AstraZeneca understands that our consumers want flexibility, especially when it comes to health information,” said Donna Holder, senior director, AstraZeneca Information Center. “This new resource enables consumers to have easier access to the information they seek through the convenience of a real-time, online channel.”
Patients can contact the AstraZeneca Information Center by telephone at 1-800-236-9933, Monday through Friday from 8 a.m. to 6 p.m. ET, excluding holidays, or by submitting an e-mail request form. In addition, CRESTOR and NEXIUM brand websites launched “Call Me Now” in October 2010. Call Me Now offers visitors the option to receive a personal phone call from an Information Center representative to help answer their questions about CRESTOR or NEXIUM without having to go through telephone prompts, wait on the line or listen to a recorded operator.
“AstraZeneca is one of the first pharmaceutical companies to use this technology, making it a very forward-thinking company in the pharmaceutical industry,” said Don Keane, vice president of marketing and product strategy for Angel, a leading provider of customer interaction solutions such as Interactive Voice Response (IVR) and chat technologies. “Click-to-chat enables consumers to engage in a live-chat session and interact directly with AstraZeneca representatives, adding another communications channel for great customer service.”
Wednesday, April 27, 2011
AstraZeneca Launches Live Click-to-Chat Feature on CRESTOR and NEXIUM Consumer Websites - News Press Release | PharmiWeb.com
via pharmiweb.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment